IVI RMA has signed a definitive agreement to acquire the North American Operations of Eugin Group, consisting of the Boston IVF fertility network and Toronto-based TRIO, from healthcare group Fresenius. The acquisition will add over 600 employees across 13 labs and 32 satellite offices to IVI RMA’s network of 10 labs and 29 satellites in North America, bringing the organization’s total headcount to more than 4,400 globally. The acquired businesses will continue to operate under their existing brands.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on FMS:
- Fresenius Medical price target raised to EUR 39 from EUR 38 at Barclays
- Fresenius Medical price target lowered to EUR 28 from EUR 32.10 at JPMorgan
- Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter
- FMS Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Fresenius Medical price target lowered to EUR 32.10 from EUR 38 at JPMorgan
